Abstract
Malnutrition is common in both adult and pediatric patients undergoing treatment for cancer. Patients commonly attribute difficulties maintaining food intake to an altered taste developed during treatment. This review summarizes what is known about taste and smell dysfunction in patients with undergoing chemotherapy as their main treatment modality. Self-reported taste and smell alterations are prevalent in upwards of 86% of cancer patients. There is some evidence for decreased taste sensitivity in cancer patients when assessed using common gustatory tests. In some patients, taste and smell alterations may continue well after their cancer treatment has been completed. Such disorders can increase distress, reduce appetite and contribute towards poor nutritional status in cancer patients. There remain no effective interventions for improving the appetite or nutritional intake of patients with cancer experiencing taste and smell changes. There is a lack of consistency in assessment methodologies for measuring taste and smell changes in cancer patients and we therefore recommend that future work use well-established methods. Research should also take into account the role of food hedonics, food flavor and texture in assessing the association between taste dysfunction, poor oral intake and malnutrition in cancer patients. Both adult and child cancer patients should be counselled on the potential impact taste and smell dysfunction can have on their appetite and oral intake.
Keywords: Cancer, chemotherapy, taste, smell, dysfunction, alteration.
Current Pharmaceutical Design
Title:Smell and Taste Disorders Resulting from Cancer and Chemotherapy
Volume: 22 Issue: 15
Author(s): Jennifer Cohen, Claire E. Wakefield and David G. Laing
Affiliation:
Keywords: Cancer, chemotherapy, taste, smell, dysfunction, alteration.
Abstract: Malnutrition is common in both adult and pediatric patients undergoing treatment for cancer. Patients commonly attribute difficulties maintaining food intake to an altered taste developed during treatment. This review summarizes what is known about taste and smell dysfunction in patients with undergoing chemotherapy as their main treatment modality. Self-reported taste and smell alterations are prevalent in upwards of 86% of cancer patients. There is some evidence for decreased taste sensitivity in cancer patients when assessed using common gustatory tests. In some patients, taste and smell alterations may continue well after their cancer treatment has been completed. Such disorders can increase distress, reduce appetite and contribute towards poor nutritional status in cancer patients. There remain no effective interventions for improving the appetite or nutritional intake of patients with cancer experiencing taste and smell changes. There is a lack of consistency in assessment methodologies for measuring taste and smell changes in cancer patients and we therefore recommend that future work use well-established methods. Research should also take into account the role of food hedonics, food flavor and texture in assessing the association between taste dysfunction, poor oral intake and malnutrition in cancer patients. Both adult and child cancer patients should be counselled on the potential impact taste and smell dysfunction can have on their appetite and oral intake.
Export Options
About this article
Cite this article as:
Cohen Jennifer, E. Wakefield Claire and G. Laing David, Smell and Taste Disorders Resulting from Cancer and Chemotherapy, Current Pharmaceutical Design 2016; 22 (15) . https://dx.doi.org/10.2174/1381612822666160216150812
DOI https://dx.doi.org/10.2174/1381612822666160216150812 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Biology of T-Type Calcium Channels
CNS & Neurological Disorders - Drug Targets Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Virulence Factors of Candida albicans Isolates from the Oral Cavities of HIV-1-Positive Patients
Current HIV Research Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry Unravelling the Genetic Susceptibility to Develop Ligament and Tendon Injuries
Current Stem Cell Research & Therapy Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Drug Coated Clay Nanoparticles for Delivery of Chemotherapeutics
Current Nanoscience The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction
Current Pharmaceutical Design Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia
Current Psychiatry Reviews Chemoprevention of Lung Pathologies by Dietary n-3 Polyunsaturated Fatty Acids
Current Medicinal Chemistry The Complex Airway in Childhood Asthma
Current Pediatric Reviews OMICS-Derived Targets for Inflammatory Gut Disorders: Opportunities for the Development of Nutrition Related Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Emerging Strategies in Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
Current Medicinal Chemistry Autophagy Inhibition in Childhood Nephroblastoma and the Therapeutic Significance
Current Cancer Drug Targets Targeting Microparticle Biogenesis: A Novel Approach to the Circumvention of Cancer Multidrug Resistance
Current Cancer Drug Targets